glp-1 agonist prediabetes Frontiers Frontiers | Mechanisms of action
Description
Pemvidutide (ALT-801) is another unimolecular once weekly GLP-1/glucagon agonist undergoing a phase 2 trial as obesity treatment, following a phase 1 trial demonstrating up to 10.3% WL at 12 weeks [73]
Glia and their cytokines in progression of neurodegeneration
Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-
BMJ Med 1(1):e000308 Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX et al (2015) Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY)
